Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quart...(Consolidated Statements of Operations Da...),Health

Date:4/28/2009

Consolidated Statements of Operations Data Three Months Ended March 31, (In thousands, except per share data) 2009 2008 (unaudited) Revenues: Collaborative research $3,605 $7,634 Subscription and license fees 563 1,259 Total revenues 4,168 8,893 Operating expenses: Research and development, including stock-based compensation of $829 and $1,127, respectively 22,976 27,802 General and administrative, including stock-based compensation of $613 and $652, respectively 4,762 5,529 Total operating expenses 27,738 33,331 Loss from operations (23,570) (24,438) Gain on long-term investments, net 517 - Interest income 327 2,781 Interest expense (666) (670) Other expense, net (945) (547) Consolidated net loss. (24,337) (22,874) Less: Net loss attributable to noncontrolling interest in Symphony Icon, Inc. 2,777 4,924 Net loss attributable to Lexicon Pharmaceuticals, Inc. $(21,560) $(17,950) Net loss attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted $(0.16) $(0.13) Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted 137,075
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)